成都先导(688222) - 2025 Q2 - 季度财报

Important Notice The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, which is unaudited and contains forward-looking statements subject to actual differences Important Notice The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, which is unaudited and contains forward-looking statements subject to actual differences - The company's board of directors, supervisory board, and senior management declare the semi-annual report content is true, accurate, and complete[4] - This semi-annual report is unaudited[5] - The report contains forward-looking statements based on subjective assumptions and judgments about future policies and economic trends, where actual results may differ and do not constitute a substantive commitment[7] - The company has no non-operating funds occupied by controlling shareholders or other related parties, nor does it provide external guarantees in violation of prescribed decision-making procedures[8] Section I Definitions This section defines common terms used in the report, including company names, shareholder names, industry-specific terms, and financial and legal terminology, ensuring accurate understanding of the content Definitions This section defines common terms used in the report, including company names, shareholder names, industry-specific terms, and financial and legal terminology, ensuring accurate understanding of the content - This section details the professional terms used in the report, covering company entities, technology platforms, drug development stages, and financial concepts, to ensure accurate understanding of the content[12][13][14][15] Section II Company Profile and Key Financial Indicators This section provides the company's basic information, stock overview, and key financial data and indicators for the reporting period, highlighting significant performance growth Company Basic Information This section introduces HitGen Inc.'s basic information, including its Chinese/English names, legal representative, registered and office addresses, website, and email, along with contact details for information disclosure Company Basic Information | Indicator | Content | | :--- | :--- | | Chinese Name | 成都先导药物开发股份有限公司 | | Chinese Abbreviation | 成都先导 | | English Name | HitGen Inc. | | Legal Representative | JIN LI (李进) | | Registered Address | 3rd Floor, Building 1, No. 88, Keyuan South Road, High-tech Zone, Chengdu, Sichuan Province | | Office Address | Chengdu Tianfu International Bio-town (No. 18, Section 2, Biocheng Middle Road, Shuangliu District, Chengdu) | | Website | http://www.hitgen.com/ | | Email | investors@hitgen.com | Contact Information | Position | Name | Phone | Email | | :--- | :--- | :--- | :--- | | Board Secretary | Geng Shiwei | 028-8519 7385 | investors@hitgen.com | | Securities Affairs Representative | Zhu Lei | 028-8519 7385 | investors@hitgen.com | Brief Introduction to Information Disclosure and Document Placement Changes The company designates specific newspapers for information disclosure, publishes its semi-annual report on the Shanghai Stock Exchange website, and keeps it available at the board of directors' office - The company designates "Shanghai Securities News," "China Securities Journal," "Securities Times," and "Securities Daily" as information disclosure newspapers[19] - The semi-annual report is published on the Shanghai Stock Exchange website (http://www.sse.com.cn/)[19](index=19&type=chunk) - The company's semi-annual report is available at the office of the board of directors[19] Overview of Company Shares/Depositary Receipts The company's A-shares are listed on the STAR Market of the Shanghai Stock Exchange, with the stock abbreviation "HitGen" and stock code "688222" Company Stock Overview | Stock Type | Stock Exchange and Board | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A-share | Shanghai Stock Exchange STAR Market | 成都先导 | 688222 | Company's Key Accounting Data and Financial Indicators In H1 2025, the company achieved a 16.58% revenue increase to 227.01 million yuan, a 390.72% rise in net profit attributable to shareholders to 50.04 million yuan, and a 2,517.66% increase in non-recurring net profit to 53.91 million yuan, driven by strong DEL business growth, milestone revenue, and improved R&D efficiency Key Accounting Data for H1 2025 | Indicator | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 227.01 million yuan | 194.72 million yuan | 16.58 | | Total Profit | 56.77 million yuan | 7.63 million yuan | 644.15 | | Net Profit Attributable to Parent Company Shareholders | 50.04 million yuan | 10.20 million yuan | 390.72 | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-recurring Items) | 53.91 million yuan | 2.06 million yuan | 2,517.66 | | Net Cash Flow from Operating Activities | 110.61 million yuan | 73.02 million yuan | 51.48 | | Net Assets Attributable to Parent Company Shareholders (Period-end) | 1.43 billion yuan | 1.39 billion yuan | 2.51 | | Total Assets (Period-end) | 1.84 billion yuan | 1.76 billion yuan | 4.89 | Key Financial Indicators for H1 2025 | Indicator | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (yuan/share) | 0.12 | 0.02 | 500.00 | | Diluted Earnings Per Share (yuan/share) | 0.12 | 0.02 | 500.00 | | Basic Earnings Per Share (Excluding Non-recurring Items) (yuan/share) | 0.13 | 0.01 | 1,200 | | Weighted Average Return on Net Assets (%) | 3.52 | 0.73 | Increased by 2.79 percentage points | | Weighted Average Return on Net Assets (Excluding Non-recurring Items) (%) | 3.79 | 0.15 | Increased by 3.64 percentage points | | R&D Investment as % of Operating Revenue (%) | 12.69 | 15.78 | Decreased by 3.09 percentage points | - DEL segment revenue increased by 40.45%, showing significant growth and contributing substantially to profit improvement[23] - UK subsidiary Vernalis recognized milestone revenue, strengthening the development of the FBDD/SBDD platform[23] - OBT segment achieved commercialization of one-stop small nucleic acid projects through delivery molecule-related services[23] - TPD segment actively explored new business models, initiating new PROTAC technology project collaborations[23] - Automated high-throughput chemical synthesis platform operated efficiently, driving ChemSer revenue growth[23] - R&D investment slightly decreased year-on-year, with significantly improved resource allocation efficiency, primarily due to UK subsidiary Vernalis adjusting R&D resource allocation[25] - Increased government subsidies and exchange gains positively impacted net profit[25] Non-recurring Gains and Losses Items and Amounts This period's non-recurring gains and losses totaled -3.87 million yuan, primarily due to government subsidies, fair value changes in financial assets and liabilities, and other non-operating income/expenses, with a negative impact from fair value changes in financial liabilities Non-recurring Gains and Losses Items and Amounts | Non-recurring Gains and Losses Item | Amount (yuan) | | :--- | :--- | | Government subsidies recognized in current profit or loss | 5.09 million yuan | | Fair value changes in financial assets and liabilities held by non-financial enterprises, and gains/losses from disposal of financial assets and liabilities | -8.52 million yuan | | Other non-operating income and expenses apart from the above | 424,720.83 | | Less: Income tax impact | 871,778.30 | | Total | -3.87 million yuan | Section III Management Discussion and Analysis This section discusses the company's industry, main business operations, core competencies, and risk factors, providing an in-depth analysis of its performance and strategic outlook Description of the Company's Industry and Main Business Operations During the Reporting Period The company specializes in small molecule and nucleic acid drug discovery and optimization, leveraging its DEL, FBDD/SBDD, OBT, and TPD platforms to offer R&D services from target gene to IND, alongside flexible business models including project equity transfer and self-developed drug sales, capitalizing on a growing global pharmaceutical market Main Business HitGen focuses on small molecule and nucleic acid drug discovery and optimization, utilizing its DEL, FBDD/SBDD, OBT, and TPD platforms to build a leading global R&D system, having synthesized over 1.2 trillion DNA-encoded compounds and possessing multiple internal drug projects in clinical and preclinical stages - The company focuses on the discovery and optimization of small molecule and nucleic acid new drugs, with core technology platforms including DEL, FBDD/SBDD, OBT, and TPD[30] - The company has completed the synthesis of over 1.2 trillion novel, diverse, and drug-like DNA-encoded compounds[30] - The company has multiple internal new drug projects, each at different clinical and preclinical stages[30] - The company's business spans North America, Europe, Asia, and Oceania, establishing collaborations with numerous internationally renowned pharmaceutical and biotechnology companies[33] Business Model The company's business model integrates new drug R&D services, new drug project equity transfers, and sales of self-developed projects, including FFS and FTE models, IP transfer fees, and milestone payments, having completed IP transfers for 8 projects during the reporting period while strictly adhering to exclusivity principles - The company's business model combines new drug R&D services, new drug project equity transfers, and the sales of self-developed projects[34] - New drug R&D services include Fee-for-Service (FFS), Full-Time Equivalent (FTE) services, drug structure IP ownership transfer fees, and milestone payments[35][36] - During the reporting period, the company completed compound intellectual property (IP) transfers for 8 projects, with a cumulative total of 118 projects (>1,100 active compound entities) having IP transferred[36][37] - By transferring all or part of the rights to new drug projects, the company can receive upfront payments, milestone revenues, and profit sharing[38] - The company's business model strictly adheres to target exclusivity and molecular structure exclusivity principles to ensure no conflicts of interest between new drug R&D projects and client screening projects[39][40] Industry Overview The global pharmaceutical market is projected to reach $1.8 trillion by 2025, with sustained growth in R&D investment, where small molecule drugs remain dominant, new chemical entities approvals are rising, and patented innovative drugs are increasing, presenting significant opportunities for the company, especially in China's rapidly expanding innovative drug market - The global pharmaceutical market size was approximately $1.48 trillion in 2022, projected to reach $1.8 trillion by 2025[41] - Global pharmaceutical R&D investment is projected to grow from $224.1 billion in 2021 to $312.9 billion in 2026, with a CAGR of approximately 6.9%[42] - China's pharmaceutical R&D investment is projected to grow from $32.7 billion in 2022 to $52.9 billion in 2026, with a CAGR of approximately 12.8%[42] - Small molecule chemical drugs still dominate the market, being the only means to treat intracellular diseases or cross the blood-brain barrier[42] - In 2024, the FDA approved 50 new drugs, including 32 new chemical entities (approximately 64%), with an estimated 30-40 new chemical entities expected annually over the next five years[43] - China's innovative drug market share is projected to increase to 70% by 2030, with generics decreasing to 25%, indicating significant growth potential for innovative drugs[43] - The company focuses on the discovery and optimization of small molecule and nucleic acid new drugs, with core technology platforms including DEL, FBDD/SBDD, OBT, and TPD[30] - The company has completed the synthesis of over 1.2 trillion DNA-encoded compounds and possesses multiple internal new drug projects at various R&D stages[30] - The business model combines new drug R&D services, new drug project equity transfers, and sales of self-developed projects, enabling continuous output of innovative drug projects and creation of high-yield long-term value[34] - New drug R&D services include FFS and FTE models, as well as IP ownership transfer fees and milestone payments, with 8 compound IP transfers completed during the reporting period[35][36][37] - The company strictly adheres to target exclusivity and molecular structure exclusivity principles, ensuring no conflicts of interest between new drug R&D projects and client screening projects[39][40] - The global pharmaceutical market was approximately $1.48 trillion in 2022, projected to reach $1.8 trillion by 2025, with continuous growth in global pharmaceutical R&D investment[41] - Small molecule chemical drugs still dominate the market, with an increasing number of new chemical entity approvals and a growing proportion of patented innovative drugs[42][43] Discussion and Analysis of Operations In H1 2025, the company's revenue grew by 16.58% to 227.01 million yuan, net profit attributable to shareholders increased by 390.72% to 50.04 million yuan, and non-recurring net profit rose by 2,517.66% to 53.91 million yuan, driven by strong growth in DEL, FBDD/SBDD (including milestone revenue), and ChemSer segments, alongside improved R&D efficiency and progress in HAILO platform and HG146 clinical trials Key Operating Data for H1 2025 | Indicator | Amount (million yuan) | Year-on-Year Growth (%) | | :--- | :--- | :--- | | Operating Revenue | 227.01 | 16.58 | | Total Profit | 56.77 | 644.15 | | Net Profit Attributable to Parent Company Owners | 50.04 | 390.72 | | Net Profit Attributable to Parent Company Owners (Excluding Non-recurring Items) | 53.91 | 2,517.66 | | Net Cash Flow from Operating Activities | 110.61 | 51.48 | - DEL segment revenue 102.19 million yuan, increased by 40.45% year-on-year, primarily due to diversified development in custom library and screening services[45] - FBDD/SBDD segment revenue 65.24 million yuan, increased by 4.15% year-on-year, mainly due to UK subsidiary Vernalis recognizing milestone revenue[45] - ChemSer segment revenue increased by 94.17% year-on-year, benefiting from the efficient operation of the automated high-throughput chemical synthesis platform[45] - R&D investment 28.81 million yuan, accounting for 12.69% of operating revenue, a 3.09 percentage point year-on-year decrease, indicating significantly improved resource allocation efficiency[46] - The HAILO (DEL+AI/ML) platform achieved phased results in models and data, high-throughput chemical/biological platforms, and project pipelines, with two new self-developed projects initiating DMTA cycles[48] - Self-developed pipeline HG146 solid tumor (ACC) project successfully advanced to Phase II clinical trials, and TPD's unique TRIM21 ligand completed molecular glue mechanism validation[47] - The company continued its collaboration with SGC, with the co-developed "Target 2035 Phase 2 Roadmap" featured in "Nature Reviews Chemistry," acknowledging its leadership in DEL technology[47] Analysis of Core Competencies During the Reporting Period The company's core competencies stem from its leading DEL, FBDD/SBDD, OBT, TPD, and AI integration technologies, boasting the world's largest DNA-encoded compound library (over 1.2 trillion molecules), strong R&D talent, 143 patents, and a flexible business model combining services with independent innovation, ensuring its leadership in early drug discovery and sustained profitability Core Competency Analysis The company's core competencies stem from its leading DEL, FBDD/SBDD, OBT, TPD, and AI integration technologies, boasting the world's largest DNA-encoded compound library (over 1.2 trillion molecules), strong R&D talent, 143 patents, and a flexible business model combining services with independent innovation, ensuring its leadership in early drug discovery and sustained profitability - The company's DEL technology is in a leading position, possessing the world's largest known small molecule compound library, with a quantity exceeding 1.2 trillion[49] - The DEL library has expanded to include new molecular types such as covalent compound libraries, protein degradation compound libraries, fragment compound libraries, linear peptide libraries, and cyclic peptide libraries[52] - FBDD/SBDD technology is highly complementary to DEL technology, especially in enhancing fragment activity and optimizing lead compounds[55] - The OBT platform possesses nucleic acid drug R&D capabilities, covering sequence design, synthesis modification, biological evaluation, and delivery system development[56][57] - The TPD platform focuses on E3 ubiquitin ligase and POI ligand discovery, with DEL technology having a unique advantage in protein degradation, and the TRIM21 ligand completing molecular glue mechanism validation[58][60][62] - AI is integrated with DEL technology, utilizing massive data to train models and accelerate the compound optimization process[62] - The company has 413 R&D personnel, with 97.58% holding bachelor's degrees or higher, including 74 PhDs and 137 Masters, demonstrating strong talent capabilities[63] - The company is one of the earliest in China and Asia to engage in large-scale DEL technology R&D and application, possessing a first-mover advantage[64] - As of the end of the reporting period, the company had cumulatively obtained 143 invention patents and 14 software copyrights, with over 300 domestic and international invention patents pending application[65] - The company offers various forms of cooperation, including new drug R&D services and new drug project equity transfers, with flexible and transparent cooperation models[66] - The company's business model combines services with independent innovation, generating continuous revenue by providing R&D services and transferring drug projects, while also independently developing innovative drug projects[67][68] Core Technologies and R&D Progress The company's core technology platforms (DEL, FBDD/SBDD, OBT, TPD) continue to innovate, with the DEL library expanding to trillions of new molecular entities and successfully identifying novel hit compounds for challenging targets. DEL and FBDD/SBDD integration significantly enhances fragment optimization. The OBT platform offers one-stop oligonucleotide drug R&D, and the TPD platform has breakthroughs in E3 ubiquitin ligase ligand development and molecular glue technology. AI is deeply integrated with DEL, achieving phased results in the HAILO platform. The self-developed HG146 solid tumor project is progressing to Phase II clinical trials, and multiple original papers have been published, with R&D investment at 12.69% of revenue - The DEL library now contains over 1.2 trillion molecules, covering over 6,000 molecular scaffolds and nearly 40,000 synthetic building blocks, with chemical reaction types upgraded to over 170[71] - The DEL library has expanded to include new molecular types such as covalent compound libraries, protein degradation compound libraries, fragment compound libraries, linear peptide libraries, and cyclic peptide libraries[74] - During the reporting period, the company completed the design and synthesis of key DEL libraries for novel molecular glue compounds[76] - DEL screening success rate reached 75%, with an average screening project cycle shortened to within 3 months, and 8 compound IP transfers completed[77] - FBDD/SBDD technology complements DEL technology, optimizing millimolar (mM) level molecular fragments into nanomolar (nM) level hit compounds, significantly shortening the optimization process[79][80] - The OBT platform provides one-stop services from oligonucleotide sequence design and special monomer synthesis to oligonucleotide conjugate synthesis, and develops various nucleic acid delivery systems[99] - The TPD platform has cumulatively completed over 50 novel E3 ubiquitin ligases, with TRIM21 completing molecular glue mechanism validation, demonstrating specific tumor cell killing effects[100][101] - The HAILO platform achieved phased results in models and data, high-throughput chemical platforms, high-throughput biological platforms, and project pipelines, with two new self-developed projects initiating DMTA cycles[102] - Self-developed pipeline HG146 solid tumor (ACC) project successfully advanced to Phase II clinical trials, HG030 US IND maintenance is normal, and HG381 project paused new subject enrollment[104][105][106][107][110] - During the reporting period, 5 original papers were published, including the monograph "DNA-Encoded Library Technology for Drug Discovery" and an article on TRIM21 molecular glue mechanism validation[112] R&D Investment | Indicator | Current Period (yuan) | Prior Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Expensed R&D Investment | 28.81 million yuan | 30.73 million yuan | -6.27 | | Total R&D Investment | 28.81 million yuan | 30.73 million yuan | -6.27 | | Total R&D Investment as % of Operating Revenue (%) | 12.69 | 15.78 | Decreased by 3.09 percentage points | R&D Project Status | Project Name | Estimated Total Investment (million yuan) | Current Period Investment (million yuan) | Cumulative Investment (million yuan) | Progress or Phased Results | | :--- | :--- | :--- | :--- | :--- | | HG146 | 250 | 7.96 | 69.52 | Solid tumor (ACC) enrollment progressing smoothly, Phase II clinical trials advancing as planned | | HG3918 | 350 | 1.59 | 10.84 | Second-generation oral small molecule inhibitor PCC confirmation phase | | HAILO | See description | 4.06 | 14.92 | Platform construction, model iteration, high-throughput chemical/biological platform integration, new self-developed projects initiating DMTA cycles | | Total | / | 13.61 | 95.28 | / | R&D Personnel Composition | Indicator | Quantity (persons) | Proportion (%) | | :--- | :--- | :--- | | Total R&D Personnel | 413 | 83.94% (of total company headcount) | | PhD | 74 | 17.92 | | Master's | 137 | 33.17 | | Bachelor's | 192 | 46.49 | | Associate's | 10 | 2.42 | | Under 30 years old | 190 | 46.00 | | 30-40 years old | 166 | 40.19 | - The company's DEL technology is in a leading position, possessing the world's largest known small molecule compound library, with a quantity exceeding 1.2 trillion[49] - The DEL library has expanded to include new molecular types such as covalent compound libraries, protein degradation compound libraries, fragment compound libraries, linear peptide libraries, and cyclic peptide libraries[52] - FBDD/SBDD technology is highly complementary to DEL technology, especially in enhancing fragment activity and optimizing lead compounds[55] - The OBT platform possesses nucleic acid drug R&D capabilities, covering sequence design, synthesis modification, biological evaluation, and delivery system development[56][57] - The TPD platform focuses on E3 ubiquitin ligase and POI ligand discovery, with DEL technology having a unique advantage in protein degradation, and the TRIM21 ligand completing molecular glue mechanism validation[58][60][62] - AI is integrated with DEL technology, utilizing massive data to train models and accelerate the compound optimization process, with the HAILO platform achieving phased results[62][88] - The company has 413 R&D personnel, with 97.58% holding bachelor's degrees or higher, including 74 PhDs and 137 Masters, demonstrating strong talent capabilities[63][123] - The company is one of the earliest in China and Asia to engage in large-scale DEL technology R&D and application, possessing a first-mover advantage[64] - As of the end of the reporting period, the company had cumulatively obtained 143 invention patents and 14 software copyrights, with over 300 domestic and international invention patents pending application[65][113] - Self-developed pipeline HG146 solid tumor (ACC) project successfully advanced to Phase II clinical trials, HG030 US IND maintenance is normal, and HG381 project paused new subject enrollment[104][105][106][107][110] - During the reporting period, 5 original papers were published, including the monograph "DNA-Encoded Library Technology for Drug Discovery" and an article on TRIM21 molecular glue mechanism validation[112] R&D Investment | Indicator | Current Period (yuan) | Prior Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Expensed R&D Investment | 28.81 million yuan | 30.73 million yuan | -6.27 | | Total R&D Investment | 28.81 million yuan | 30.73 million yuan | -6.27 | | Total R&D Investment as % of Operating Revenue (%) | 12.69 | 15.78 | Decreased by 3.09 percentage points | Risk Factors The company faces risks including new drug R&D failure, technological obsolescence, loss of core talent, management challenges from expanding operations, high customer concentration, exchange rate fluctuations, accounts receivable, tax policy changes, and fair value volatility, compounded by intensifying industry competition and macroeconomic factors like international tensions Core Competency Risks The company faces risks of new drug R&D failure, particularly for innovative projects targeting new mechanisms, and the potential for its DEL and other core technologies to be superseded by existing or emerging innovative drug discovery methods - The company's self-developed new drug projects often target new targets/mechanisms, carrying higher R&D failure risks compared to improved new drugs or generics[124] - DEL technology faces the risk of being replaced by existing technologies and other innovative drug screening methods[124] - The company's two mature drug discovery technologies (DEL, FBDD/SBDD) and other emerging core technologies (STO, TPD) still face risks of R&D failure and being replaced by new technologies[125] Operating Risks The company faces risks of core technical talent loss and intellectual property leakage due to intense competition in pharmaceutical R&D, as well as integration challenges from expanding operations, particularly after acquiring UK-based Vernalis, and potential profit decline due to high customer concentration or underperforming domestic market development - The company faces risks of core technical talent loss and resulting core technology leakage, which could adversely affect its competitiveness and profitability[126] - After acquiring UK company Vernalis, there is a management risk of failing to achieve efficient integration and synergistic development due to differences in regional culture, political environment, and management styles[126] - The company's customer concentration is relatively high; if major clients' operating conditions deteriorate or the company fails to meet client demands, and domestic market client development falls short of expectations, profits may decline[127] Financial Risks The company faces exchange rate risks due to a high proportion of overseas revenue settled in currencies like USD and GBP, potentially leading to exchange losses. Increased accounts receivable pose collection risks, changes in tax policies could raise overall tax burdens, and fair value fluctuations of financial assets (e.g., equity investments, private equity funds) may impact performance - The company has a high proportion of overseas revenue, primarily settled in USD and GBP, and unfavorable exchange rate fluctuations could adversely affect operating performance[128] - As revenue increases, accounts receivable balances also rise, posing a risk of bad debts if market conditions or major clients' creditworthiness deteriorate[129] - If national tax preferential policies undergo significant changes, the company's overall tax burden may change, adversely affecting future operating performance[129] - Fair value changes of financial assets measured at fair value (such as equity investments and private equity fund interests) are significantly affected by R&D progress and market fluctuations, potentially impacting the company's performance[129] Industry Risks The pharmaceutical R&D industry faces intensifying competition from established international players and emerging domestic biotech companies. Additionally, the company's new drug R&D service revenue is highly dependent on the overall R&D investment of global pharmaceutical enterprises, and a decline in industry R&D spending could adversely affect its business development and revenue - Competition in the pharmaceutical R&D industry is intensifying, with the company facing competition from established international rivals and emerging domestic biotechnology companies introducing new technologies[130] - The company's new drug R&D service revenue is highly dependent on the R&D investment intensity of its client base (multinational pharmaceutical companies, international biotechnology companies, and domestic innovative pharmaceutical enterprises)[130] Macro-environmental Risks A significant portion of the company's revenue comes from overseas, making its international operations vulnerable to changes in laws, policies, political and economic environments, international tensions, and trade sanctions in host countries, potentially hindering global business development. The company clarifies its DEL technology does not involve human gene sequence analysis, thus unrelated to the US Biosecurity Act draft - The company's overseas revenue accounts for a significant portion of its main business income, and its international operations are affected by laws, regulations, industrial policies, political and economic environmental changes, international tensions, and trade sanctions in the host countries and regions[131] - The company declares that its DEL technology does not involve any human gene sequence analysis business and is unrelated to the scope restricted by the US Biosecurity Act draft[132] - The company's self-developed new drug projects often target new targets/mechanisms, carrying higher R&D failure risks[124] - DEL technology and other emerging core technologies face the risk of being replaced by existing technologies or other innovative drug screening methods[124][125] - The company faces risks of core technical talent loss and core technology leakage[126] - Expanding operations, especially after acquiring UK company Vernalis, presents integration risks due to differences in regional culture, political environment, and management styles[126] - The company's customer concentration is relatively high; if major client demand decreases or domestic market development falls short of expectations, performance may be adversely affected[127] - With a high proportion of overseas revenue, the company faces exchange loss risks from significant fluctuations in exchange rates between settlement currencies like USD and GBP and RMB[128] - Increased accounts receivable balances pose a risk of delayed or uncollectible payments if future market conditions or major clients' creditworthiness deteriorate[129] - Significant changes in tax preferential policies could lead to an increase in the company's overall tax burden[129] - Fair value changes of financial assets measured at fair value (such as equity investments and private equity fund interests) are significantly affected by R&D progress and market fluctuations, potentially impacting performance[129] - Competition in the pharmaceutical R&D industry is intensifying, facing competition from established international rivals and emerging domestic enterprises introducing new technologies[130] - The company's revenue is highly dependent on the R&D investment intensity of global multinational pharmaceutical companies, international biotechnology companies, and other clients[130] - Overseas business is affected by laws, regulations, industrial policies, political and economic environmental changes, and international tensions in the host countries and regions[131] - The company declares that its DEL technology does not involve any human gene sequence analysis business and is unrelated to the scope restricted by the US Biosecurity Act draft[132] Key Operating Performance During the Reporting Period During the reporting period, the company's main business revenue increased by 16.63% to 226.94 million yuan, driven by a 40.45% growth in the DEL segment and a 94.17% increase in the ChemSer segment, while the FBDD/SBDD segment grew by 4.15% due to milestone revenue, and overall gross profit margin improved by 7.23 percentage points to 53.82% Main Business Revenue Composition | Business Type | Current Period (yuan) | Prior Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | DNA-Encoded Library Platform (DEL) | 102.19 million yuan | 72.76 million yuan | 40.45 | | Fragment-Based and Structure-Based Drug Design Platform (FBDD/SBDD) | 65.24 million yuan | 62.64 million yuan | 4.15 | | Oligonucleotide-Based Therapeutics Platform (OBT) | 27.85 million yuan | 28.81 million yuan | -3.35 | | Targeted Protein Degradation Platform (TPD) | 7.53 million yuan | 8.25 million yuan | -8.67 | | Biological Services (BioSer) | 3.38 million yuan | 8.37 million yuan | -59.59 | | Chemical Services (ChemSer) | 18.72 million yuan | 9.64 million yuan | 94.17 | | Integrated Drug Discovery Services (IDD) | 1.14 million yuan | 3.15 million yuan | -63.77 | | Other Services (Others) | 0.89 million yuan | 0.97 million yuan | -7.97 | | Total | 226.94 million yuan | 194.59 million yuan | 16.63 | - DEL segment revenue increased by 40.45% year-on-year, primarily due to more flexible and diversified custom library and screening services, especially strong progress in DEL library customization[134] - FBDD/SBDD segment revenue increased by 4.15% year-on-year, mainly due to UK subsidiary Vernalis recognizing milestone revenue[134] - OBT segment revenue decreased by 3.35% year-on-year, but achieved commercialization of one-stop small nucleic acid projects through delivery molecule-related services[134] - TPD segment revenue decreased by 8.67% year-on-year, primarily due to changes in project execution and delivery cycles resulting from new business model exploration[134] - ChemSer segment revenue increased by 94.17% year-on-year, benefiting from the efficient operation of the independently designed and built automated high-throughput chemical synthesis platform[135] Gross Profit Margin by Business Segment | Business Type | Current Period Gross Profit Margin (%) | Prior Period Gross Profit Margin (%) | Change | | :--- | :--- | :--- | :--- | | DNA-Encoded Library Platform (DEL) | 76.14 | 66.82 | Increased by 9.32 percentage points | | Fragment-Based and Structure-Based Drug Design Platform (FBDD/SBDD) | 32.53 | 39.06 | Decreased by 6.53 percentage points | | Oligonucleotide-Based Therapeutics Platform (OBT) | 34.16 | 22.64 | Increased by 11.52 percentage points | | Targeted Protein Degradation Platform (TPD) | 56.01 | 31.23 | Increased by 24.78 percentage points | | Biological Services (BioSer) | 22.89 | 41.39 | Decreased by 18.50 percentage points | | Chemical Services (ChemSer) | 41.67 | 33.38 | Increased by 8.29 percentage points | | Integrated Drug Discovery Services (IDD) | 5.88 | 25.09 | Decreased by 19.21 percentage points | | Other Services (Others) | 87.41 | 104.79 | Decreased by 17.38 percentage points | | Overall Gross Profit Margin | 53.82 | 46.59 | Increased by 7.23 percentage points | Analysis of Main Business During the reporting period, the company's operating revenue increased by 16.58%, while operating costs rose by 0.91%. Financial expenses significantly changed due to increased exchange gains, and net cash flow from operating activities grew by 51.48% due to higher sales collections. Net cash flow from investing activities sharply declined due to differences in structured deposit rollover cycles. Other income significantly increased due to higher government subsidies, and fair value change gains/losses were negative due to fair value changes in trading financial liabilities Financial Statement Items Variation Analysis | Item | Current Period (yuan) | Prior Period (yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 227.01 million yuan | 194.72 million yuan | 16.58 | | Operating Costs | 104.87 million yuan | 103.92 million yuan | 0.91 | | Selling Expenses | 9.19 million yuan | 9.72 million yuan | -5.37 | | Administrative Expenses | 36.96 million yuan | 38.73 million yuan | -4.58 | | Financial Expenses | -11.70 million yuan | -2.75 million yuan | Not applicable | | R&D Expenses | 28.81 million yuan | 30.73 million yuan | -6.27 | | Net Cash Flow from Operating Activities | 110.61 million yuan | 73.02 million yuan | 51.48 | | Net Cash Flow from Investing Activities | -52.60 million yuan | 27.03 million yuan | -294.61 | | Net Cash Flow from Financing Activities | -0.06 million yuan | -33.42 million yuan | Not applicable | | Taxes and Surcharges | 0.83 million yuan | 1.31 million yuan | -36.57 | | Other Income | 15